// App-Quantinova.ai

P6-09-30 : Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab

Researchers

Presenter

  • PS Blanchette

Principal Investigators

  • DN Desautels

  • G Pond

  • JMS Bartlett

  • S Nofech-Mozes

  • M Yaffe

  • KI Pritchard

Medical Centers

  • Sunnybrook Research Institute, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

  • McMaster University, Hamilton, ON, Canada

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Alpha thalassemia mental retardation X-linked protein

  • Alkaline phosphatase

  • Neutrophil lymphocyte ratio

  • Platelet-lymphocyte ratio

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Alkaline phosphatase

  • Trastuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved